Ms2000647-0017- A Phase II, Multicenter, Open Label Study Of Bintrafusp Alfa (M7824) Monotherapy In Participants With Advanced, Unresectable Cervical Cancer With Disease Progression During Or After Platinum-Containing Chemotherapy
Posted Date: Nov 24, 2020
- Investigator: Amanda Jackson
- Specialties: Cancer, Cervical Cancer, Oncology
- Type of Study: Drug
The main purpose of this study is to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy. The primary outcome measured for this study is Confirmed Objective Response.
Criteria:
To Be Eligible: Must Have Advanced Unresectable And/Or Metastatic Cervical Cancer With Disease Progression During Or After The Prior Platinum-Containing Chemotherapy, Ecog 0-1, Life Expectancy >12 Weeks, Measurable Disease, Adequate Organ Function Per Protocol, No Active Cns Metastases, No Co-Morbidities Deemed Severe By The Investigator
Keywords:
Cervical Cancer
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com